Treatment considerations for patients experiencing rapid-cycling bipolar disorder.
Antai-Otong
Deborah
D
deborah-antai-otong@med.va.gov
D000928:Antidepressive Agents / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D006801:Humans; D000077213:Lamotrigine; D016651:Lithium Carbonate / Q000627:therapeutic use; D009730:Nursing Assessment; D010347:Patient Care Planning; D018579:Patient Selection; D010507:Periodicity; D017410:Practice Guidelines as Topic; D011568:Psychiatric Nursing / Q000458:organization & administration*; D011569:Psychiatric Status Rating Scales; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D017211:Treatment Failure; D014227:Triazines / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D000928:Antidepressive Agents; D018692:Antimanic Agents; D014227:Triazines; D016651:Lithium Carbonate; D014635:Valproic Acid; D000077213:Lamotrigine